HSP -
MCID: HNC001
MIFTS: 61

Henoch-Schoenlein Purpura (HSP -)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Nephrological diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Henoch-Schoenlein Purpura

MalaCards integrated aliases for Henoch-Schoenlein Purpura:

Name: Henoch-Schoenlein Purpura 11 14 16 71
Henoch-Schonlein Purpura 11 19 58 53
Iga Vasculitis 58 75 43 33
Anaphylactoid Purpura 19 58 33
Rheumatoid Purpura 58 75 71
Allergic Purpura 11 31 33
Immunoglobulin a Vasculitis 19 58
Henoch-Schönlein Purpura 75 33
Purpura Rheumatica 58 71
Vascular Purpura 19 75
Immunoglobulin-a Vasculitis 19
Purpura, Schonlein-Henoch 19
Purpura, Schönlein-Henoch 75
Henoch Schonlein Purpura 19
Schönlein-Henoch Purpura 33
Henoch-Schnlein Purpura 11
Henoch-Scholein Purpura 11
Purpura, Autoimmune 11
Autoimmune Purpura 11
Hsp - 33

Characteristics:


Prevelance:

Immunoglobulin a Vasculitis: 1-9/100000 (Norway) 58

Age Of Onset:

Immunoglobulin a Vasculitis: Childhood 58

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Henoch-Schoenlein Purpura

GARD: 19 Henoch-Schonlein purpura (HSP), also called immunoglobulin A vasculitis (IgAV), is a vascular disease that primarily affects small blood vessels. The disease is characterized by abnormal deposits of immunoglobulin A (an antibody) in the blood vessels, leading to their inflammation (vasculitis). The small vessels of the skin, joints, kidneys, and digestive organs are particularly involved. Signs and symptoms usually begin suddenly (and progress over days) and may include purple-colored spots on the skin (purpura); joint pain; and gastrointestinal problems such as abdominal pain, nausea, bloody stools, and rarely, severe complications requiring surgery. People with HSP may also develop glomerulonephritis (injury to the kidneys caused by inflammation) and poor kidney function, which may result in swelling of parts of the body or face (edema), and blood and protein in the urine (hematuria and proteinuria). Most cases of HSP occur in children and go away without causing serious or long-term health problems. Less commonly, the disease affects adults and may be more severe, leading to chronic kidney disease and kidney failure. The cause of HSP is not completely understood, but research indicates that genes (especially those involved in regulating the immune system) may play a key role in predisposing a person to HSP, as well as its severity. However, while genes may increase the risk of developing the disease (and in some cases more than one family member has HSP), the disease itself is not inherited. The diagnosis of HSP may be made based on symptoms, blood and urine tests, imaging studies, and/or a biopsy of the skin or kidney.

MalaCards based summary: Henoch-Schoenlein Purpura, also known as henoch-schonlein purpura, is related to purpura and acute kidney failure. An important gene associated with Henoch-Schoenlein Purpura is MEFV (MEFV Innate Immunity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and Complement cascade. The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and bone, and related phenotypes are nausea and vomiting and hematuria

Disease Ontology: 11 A hypersensitivity vasculitis that is characterized by purpura (purplish plaques), arthralgia, gastrointestinal upset, and/or glomerulonephritis, and may be related to increased immune response following an infection.

Orphanet: 58 A rare, small-vessel vasculitis characterized by skin purpura, arthritis, abdominal and/or renal involvement, IgA tissue deposits (arterioles, capillaries, and venules) and circulating IgA immune complexes.

Wikipedia 75 Iga vasculitis: Henoch-Schönlein purpura (HSP), also known as IgA vasculitis, is a disease of the skin, mucous... more...

Vascular purpura: Purpura (/ˈpɜːrpjʊərə/) is a condition of red or purple discolored spots on the skin that do not blanch... more...

Related Diseases for Henoch-Schoenlein Purpura

Diseases related to Henoch-Schoenlein Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1350)
# Related Disease Score Top Affiliating Genes
1 purpura 31.8 TNF CRP CD79A C3
2 acute kidney failure 30.9 PRTN3 ALB ACE
3 duodenitis 30.9 TNF CRP ALB
4 microvascular complications of diabetes 5 30.8 VCAM1 ICAM1 ALB ACE
5 renal tuberculosis 30.8 CRP ALB
6 pulmonary hemosiderosis 30.8 PRTN3 MPO CRP
7 brucellosis 30.8 TNF MPO MEFV CRP
8 familial mediterranean fever 30.8 TNF MEFV CRP
9 intestinal obstruction 30.7 TNF CRP ALB
10 orchitis 30.7 TNF CRP CCR6
11 allergic cutaneous vasculitis 30.7 PRTN3 MPO
12 superior mesenteric artery syndrome 30.7 CRP ALB
13 testicular torsion 30.7 TNF MPO CRP
14 angina pectoris 30.7 TNF ICAM1 CRP ACE
15 exudative glomerulonephritis 30.7 CFHR2 C3
16 acute pancreatitis 30.6 TNF MPO ICAM1 CRP
17 central retinal artery occlusion 30.6 PRTN3 MPO CRP
18 mitral valve insufficiency 30.6 CRP ALB ACE
19 periodontitis 30.6 TNF MPO ICAM1 CRP
20 microscopic polyangiitis 30.6 PRTN3 MPO
21 drug allergy 30.6 CRP ALB ACE
22 compartment syndrome 30.6 TNF CRP ALB
23 kawasaki disease 30.6 VCAM1 TNF CRP
24 pharyngitis 30.6 TNF MEFV CRP CCR6
25 mononeuritis multiplex 30.5 TNF PRTN3 MPO CRP
26 pyuria 30.5 PRTN3 CRP C3 ALB
27 epidermolysis bullosa dystrophica, autosomal dominant 30.5 C3 ALB
28 retinal artery occlusion 30.5 ICAM1 CRP ACE
29 membranous nephropathy 30.5 CFHR2 CD79A ALB
30 macular retinal edema 30.5 TNF ICAM1 ALB ACE
31 food allergy 30.5 TNF RNASE3 ICOSLG CCR6
32 epidural abscess 30.5 CRP ALB
33 rheumatic heart disease 30.5 VCAM1 TNF ACE
34 dental caries 30.5 CRP CD79A ALB ACE
35 cervical adenitis 30.5 TNF MEFV CRP
36 autoimmune glomerulonephritis 30.5 ICOSLG CFHR2 CCR6
37 subacute bacterial endocarditis 30.5 PRTN3 MPO CRP ALB
38 tonsillitis 30.4 TNF MPO CD79A
39 osteomyelitis 30.4 TNF MEFV CRP
40 clostridium difficile colitis 30.4 CRP CCR6 ALB
41 hypertensive retinopathy 30.4 CRP ALB ACE
42 viral infectious disease 30.4 TNF ICOSLG ICAM1 CCR6
43 hidradenitis suppurativa 30.4 TNF MEFV CRP
44 immune-complex glomerulonephritis 30.4 PRTN3 ICOSLG CFHR2 C3 ALB
45 mesangial proliferative glomerulonephritis 30.4 CFHR2 CD79A C3 ALB
46 graves' disease 30.4 VCAM1 MPO ICOSLG ICAM1
47 ileus 30.4 TNF ICAM1 CRP
48 aortic valve insufficiency 30.4 CRP ALB ACE
49 diabetes mellitus, ketosis-prone 30.4 CRP ALB ACE
50 renal hypertension 30.4 CRP ALB ACE

Comorbidity relations with Henoch-Schoenlein Purpura via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease

Graphical network of the top 20 diseases related to Henoch-Schoenlein Purpura:



Diseases related to Henoch-Schoenlein Purpura

Symptoms & Phenotypes for Henoch-Schoenlein Purpura

Human phenotypes related to Henoch-Schoenlein Purpura:

58 30 (show all 36)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002017
2 hematuria 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000790
3 abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002027
4 arthralgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002829
5 purpura 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000979
6 skin rash 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000988
7 bruising susceptibility 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000978
8 vasculitis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002633
9 gastrointestinal infarctions 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0005244
10 pustule 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0200039
11 arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001369
12 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
13 skin ulcer 58 30 Frequent (33%) Frequent (79-30%)
HP:0200042
14 anorexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002039
15 myalgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003326
16 migraine 58 30 Frequent (33%) Frequent (79-30%)
HP:0002076
17 erythema 58 30 Frequent (33%) Frequent (79-30%)
HP:0010783
18 orchitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0100796
19 infectious encephalitis 30 Frequent (33%) HP:0002383
20 seizure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001250
21 muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001324
22 optic atrophy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000648
23 proteinuria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000093
24 renal insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000083
25 hemiplegia/hemiparesis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004374
26 glomerulopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100820
27 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
28 macule 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012733
29 urticaria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001025
30 episcleritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100534
31 angioedema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100665
32 restrictive ventilatory defect 30 Occasional (7.5%) HP:0002091
33 encephalitis 58 Frequent (79-30%)
34 vascular skin abnormality 58 Frequent (79-30%)
35 edema 58 Occasional (29-5%)
36 restrictive deficit on pulmonary function testing 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Henoch-Schoenlein Purpura:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.93 ACE ALB C1GALT1 C1GALT1C1 C3 CCR6
2 immune system MP:0005387 9.8 ACE ALB C1GALT1 C3 CCR6 CD79A
3 hematopoietic system MP:0005397 9.4 ACE C1GALT1 C3 CCR6 CD79A ICAM1

Drugs & Therapeutics for Henoch-Schoenlein Purpura

Drugs for Henoch-Schoenlein Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
11 Antirheumatic Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Immunologic Factors Phase 4
14 Anti-Infective Agents Phase 4
15 Antineoplastic Agents, Hormonal Phase 4
16 Hormones Phase 4
17 Hormone Antagonists Phase 4
18 Antiemetics Phase 4
19 glucocorticoids Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Gastrointestinal Agents Phase 4
22 Neuroprotective Agents Phase 4
23
Methylprednisolone Acetate Phase 4 584547
24 Protective Agents Phase 4
25 Dermatologic Agents Phase 4
26 Calcineurin Inhibitors Phase 4
27 Cyclosporins Phase 4
28 Antifungal Agents Phase 4
29
Colchicine Approved Phase 3 64-86-8 2833 6167
30
Rituximab Approved Phase 3 174722-31-7
31 Antimitotic Agents Phase 3
32 Tubulin Modulators Phase 3
33 Antibodies, Monoclonal Phase 3
34 Antineoplastic Agents, Immunological Phase 3
35
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
36
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
38
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
39
Benazepril Approved, Investigational Phase 2 86541-75-5 5362124
40
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
41
Dipyridamole Approved Phase 1, Phase 2 58-32-2 3108
42
Heparin, bovine Approved, Investigational, Withdrawn Phase 1, Phase 2 9005-49-6 22833565 9812414 772
43
Reviparin Approved, Investigational Phase 1, Phase 2 9041-08-1
44
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
45
Lenograstim Approved, Investigational Phase 2 135968-09-1
46
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
47
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
48
Infliximab Approved Phase 2 170277-31-3
49
Azathioprine Approved Phase 2 446-86-6 2265
50
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety Completed NCT03222687 Phase 4 tacrolimus;prednisone
2 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
3 Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Recruiting NCT04008316 Phase 3 Colchicine
4 Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT05329090 Phase 3 Rituximab Injection;placebo
5 The Research of Standard Diagnosis and Treatment for Severe Henoch-Schonlein Purpura in Children Unknown status NCT02540720 Phase 2 Dexamethasone;Gamma globulin
6 The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children Unknown status NCT02532790 Phase 2 Prednisone;ACEI
7 The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children Unknown status NCT02532777 Phase 2 Prednisone;Cyclophosphamide(CTX);Mycophenolate mofetil(MMF);Leflunomide(LEF);Angiotensin-converting enzyme inhibitor(ACEI);Methylprednisolone
8 Demonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome Differentiation Unknown status NCT03591471 Phase 1, Phase 2 Glycosides Of Tripterygium Wilfordii Hook(GTW);Sulfotanshinone Sodium Injection;Chinese herbs based on syndrome differentiation;Prednisone Acetate Tablets;Benazepril Hydrochloride Tablets;Low Molecular Weight Heparin Calcium Injection;Dipyridamole Tab 25 MG;Chinese medicine placebo
9 Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III Unknown status NCT00060099 Phase 2
10 A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy Unknown status NCT01389583 Phase 2 AUY922
11 A Phase 1-2 Ascending Dose Study To Assess The Pharmacodynamics, Pharmacokinetics, And Safety Of Hsp-130 In Subjects With Non-metastatic Breast Cancer Following Single-dose And Multiple-dose Administration By Subcutaneous Injection Completed NCT02650193 Phase 2 HSP-130
12 Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3 Completed NCT00054041 Phase 2
13 A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors Completed NCT01259089 Phase 1, Phase 2 erlotinib hydrochloride;Hsp90 inhibitor AUY922
14 Design and Validation of a Modular Physiotherapy Concept for the Treatment of Hereditary Spastic Spinal Paralysis (HSP) - a Randomized Study Completed NCT03961906 Phase 2
15 A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma Completed NCT01200238 Phase 2 STA-9090
16 Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and Children Recruiting NCT05168475 Phase 2
17 A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases Recruiting NCT05003986 Phase 2 Sparsentan
18 A Randomized Multicenter Study for Isolated Skin Vasculitis Recruiting NCT02939573 Phase 2 Colchicine;Dapsone;Azathioprine
19 A Phase 1 Study Assessing The Pharmacodynamic And Pharmacokinetic Equivalence Of HSP-130 With US-approved Neulasta (Registered) And EU-approved Neulasta (Registered) Administered As A Single Subcutaneous Dose To Healthy Volunteers Completed NCT02629289 Phase 1 HSP-130;US-approved Neulasta;EU-approved Neulasta
20 Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors Completed NCT01246102 Phase 1 AT13387
21 Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura Unknown status NCT01610830
22 Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis Unknown status NCT02878018 Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula;angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
23 A Single Center Randomized Controlled Clinical Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules Unknown status NCT04623866 Early Phase 1 Huaiqinhuang;valsartan
24 Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study) Unknown status NCT00230412
25 CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura) Completed NCT00190229 Cyclophosphamide
26 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292
27 MMF Versus Intravenous CTX Pulses in the Treatment of Adult Severe Henoch-Schonlein Purpura Nephritis Completed NCT00301613 Mycophenolate mofetil
28 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
29 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
30 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
31 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
32 The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura Completed NCT04387942 IL-2
33 Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura Completed NCT02317133
34 Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies. Completed NCT01715623
35 SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP) Completed NCT04256681
36 The Effect of Glutamine Infusion on the Inflammatory Response and HSP-70 in BMNCs During Human Experimental Completed NCT00780520
37 Descriptive Study About a Strategy of Micronutrient Management in Parturient and Layered Women With Proteochoc®, a Dietary Supplement Rich in Porphyra HSP® Completed NCT02967796
38 Study of RNA and Heat Shock Protein (HSP) Derived Biomarkers in Radiation-induced Fibrosis in Patients Treated for Breast Cancer. Completed NCT03000764
39 Studying Non-motor Symptoms in Patients With Hereditary Spastic Paraplegia (HSP) Compared to Healthy Controls Completed NCT03204773
40 Detection of Nontuberculous Mycobacterial co-Infection Using Duplex PCR for Mycobacterial Hsp 65 Gene and Its Clinical Significance in Patients With Smear Positive Pulmonary Tuberculosis Completed NCT00567151
41 Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS): Fundamental Observational in Vitro Study Using Samples From a Collection Completed NCT02873832
42 The Vasculitis Pregnancy Registry (V-PREG) Recruiting NCT02593565
43 VCRC Tissue Biorepository Collection Protocol Recruiting NCT02967068
44 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
45 Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura Recruiting NCT03647852 Methylprednisolone;IVIG;other basic supportive treatment
46 Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) Recruiting NCT04712812
47 Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors. Recruiting NCT04628806
48 Recherche d'un Marqueur Pronostique de l'Atteinte rénale du Purpura Rhumatoïde de l'Enfant. Validation de la méthode de détection Des IgA1 Avec Gradient de la Glycosylation Par spectrométrie de Masse Active, not recruiting NCT04655378
49 A Pilot Study of Shockwave Therapy for Lower Extremity Spasticity in Persons With Genetically-Confirmed HSP Not yet recruiting NCT05411627
50 Effect of Bacterial Colonization and Extracellular HSP-70 Expression in Sub-Glottic Secretions on Ventilator Free Days in Patients Receiving Mechanical Ventilation for Respiratory Failure or Airway Protection Withdrawn NCT02311296

Search NIH Clinical Center for Henoch-Schoenlein Purpura

Cochrane evidence based reviews: iga vasculitis

Genetic Tests for Henoch-Schoenlein Purpura

Anatomical Context for Henoch-Schoenlein Purpura

Organs/tissues related to Henoch-Schoenlein Purpura:

MalaCards : Skin, Kidney, Bone, T Cells, Breast, Skeletal Muscle, Lung

Publications for Henoch-Schoenlein Purpura

Articles related to Henoch-Schoenlein Purpura:

(show top 50) (show all 17858)
# Title Authors PMID Year
1
Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. 53 62
20056836 2010
2
Vasculitic IgA nephropathy: prognosis and outcome. 53 62
19342865 2009
3
Pathogenesis-related adhesion molecules in Henoch-Schonlein vasculitis. 53 62
17701178 2008
4
Cardiac manifestations of Henoch-Schoenlein purpura: IgA mediated vasculitis or Rheumatic fever? 53 62
17047991 2007
5
Efficacy of tonsillectomy plus methylprednisolone pulse therapy for a child with Henoch-Schoenlein purpura nephritis. 53 62
17347555 2007
6
[Role of mast cells and eosinophil cationic protein in the pathogenesis of Henoch-Schonlein purpura nephritis]. 53 62
16836844 2006
7
Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway. 53 62
16634798 2006
8
[Anti-mesangial cell autoantibodies and their target antigens in lupus nephritis]. 53 62
14728876 2003
9
Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. 53 62
12538733 2003
10
A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. 53 62
12464682 2002
11
Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. 53 62
12453297 2002
12
The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura. 53 62
12390327 2002
13
[Acute hemorrhagic edema of childhood and its differentiation from Schoenlein-Henoch purpura]. 53 62
11370431 2001
14
Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. 53 62
11091287 2000
15
Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schönlein purpura and pediatric systemic lupus erythematosus. 53 62
10990243 2000
16
Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. 53 62
10709887 2000
17
[Anti-myeloperoxidase and anti-lactoferrin antibodies in patients with IgA nephropathy and Henoch-Schönlein purpura]. 53 62
10097638 1999
18
Clinical features and natural history of IgA nephropathy. 53 62
10392260 1999
19
Immunogold labelling of cytokines in glomeruli in children with various renal diseases. 53 62
10516492 1999
20
Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. 53 62
9568852 1998
21
Is there IgA from gut mucosal origin in the serum of children with Henoch-Schönlein purpura? 53 62
9557162 1998
22
Eosinophil cationic protein in Henoch-Schönlein purpura and in IgA nephropathy. 53 62
9438647 1997
23
Properties of circulating IgA molecules in Henoch-Schönlein purpura nephritis with focus on neutrophil cytoplasmic antigen IgA binding (IgA-ANCA): new insight into a debated issue. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura in adults and in children. 53 62
9394310 1997
24
Plasma E-selectin and ICAM-1 in acute Henoch-Schönlein purpura. 53 62
9279172 1997
25
Circulating soluble selectins in Kawasaki disease. 53 62
9182890 1997
26
[Diagnostic value of serum IGA-fibronectin aggregates to IGA nephropathy]. 53 62
9812564 1997
27
Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. 53 62
9002541 1997
28
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy. 53 62
9002298 1996
29
Circulating adhesion molecules ICAM-1, E-selectin, and von Willebrand factor in Henoch-Schönlein purpura. 53 62
9014604 1996
30
Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. 53 62
8915239 1996
31
IgA deposition in the skin of patients with alcoholic liver disease. 53 62
8720981 1996
32
No pathogenic role of enhanced plasma IgA binding capacity to fibronectin and IgA-fibronectin aggregates in Henoch-Schönlein purpura. 53 62
8893175 1996
33
von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. 53 62
8580019 1995
34
Evolution of immunoglobulin A nephropathy into Henoch-Schönlein purpura in an adult patient. 53 62
7847363 1995
35
Expression of MxA protein in inflammatory dermatoses. 53 62
7822763 1995
36
Sequential occurrence of IgA nephropathy and Henoch-Schönlein purpura: support for common pathogenesis. 53 62
7696119 1994
37
A case report suggesting a common pathogenesis for IgA nephropathy and Henoch-Schönlein purpura. 53 62
7696118 1994
38
IgA anticardiolipin antibodies associated with Henoch-Schönlein purpura. 53 62
7962736 1994
39
Lack of IgA antineutrophil cytoplasmic antibodies in Henoch-Schönlein purpura and IgA nephropathy. 53 62
7923914 1994
40
[Studies on urinary protein components in renal disease in children, II--Comparison between children with orthostatic albuminuria and children with remission of glomerulonephritis]. 53 62
7815746 1994
41
Henoch-Schönlein purpura in a patient with diabetic nephropathy. 53 62
8079978 1994
42
Henoch-Schoenlein purpura due to streptokinase. 53 62
8288725 1993
43
Serum anti-streptococcal IgA, IgG and IgM antibodies in IgA-associated diseases. 53 62
8503268 1993
44
Genetic study on HLA class II and class III region in the disease associated with IgA nephropathy. 53 62
8105396 1993
45
Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis. 53 62
1327645 1992
46
Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. 53 62
1350908 1992
47
Accelerated expression of secreted alpha-chain gene in anaphylactoid purpura. 53 62
1400899 1992
48
[Studies on Hanganutziu-Deicher antibodies in renal diseases]. 53 62
1316976 1992
49
Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. 53 62
1928066 1991
50
Renal expression of intercellular adhesion molecule-1 in different forms of glomerulonephritis. 53 62
1682080 1991

Variations for Henoch-Schoenlein Purpura

Copy number variations for Henoch-Schoenlein Purpura from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210503 6 30400000 36600000 Copy number C4B Henoch-schoenlein purpura

Expression for Henoch-Schoenlein Purpura

Search GEO for disease gene expression data for Henoch-Schoenlein Purpura.

Pathways for Henoch-Schoenlein Purpura

Pathways related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 VCAM1 TNF RNASE3 PRTN3 MPO MEFV
2
Show member pathways
12.28 ICAM1 CRP CFHR2 C3 ALB
3
Show member pathways
11.41 VCAM1 TNF ICAM1
4 11.37 VCAM1 TNF ICAM1
5 11.26 VCAM1 TNF ICAM1
6 11.2 TNF ICOSLG CRP CD79A C3
7 10.9 VCAM1 ICAM1 C3
8 10.13 VCAM1 TNF MPO ICAM1

GO Terms for Henoch-Schoenlein Purpura

Cellular components related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.8 VCAM1 TNF ICOSLG ICAM1 CD79A CCR6
2 azurophil granule lumen GO:0035578 9.76 RNASE3 PRTN3 MPO C3
3 extracellular space GO:0005615 9.68 ACE ALB C3 CFHR2 CRP ICAM1

Biological processes related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane to membrane docking GO:0022614 9.56 VCAM1 ICAM1
2 O-glycan processing, core 1 GO:0016267 9.46 C1GALT1 C1GALT1C1
3 response to gold nanoparticle GO:1990268 9.26 TNF MPO
4 cellular response to amyloid-beta GO:1904646 9.17 VCAM1 TNF MIR98 ICAM1

Molecular functions related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase activity GO:0016263 8.92 C1GALT1C1 C1GALT1

Sources for Henoch-Schoenlein Purpura

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....